mTOR is frequently active in GH-secreting pituitary adenomas without influencing their morphopathological features

Emir Ahmed Sajjad1, Grzegorz Zieliński, Maria Maksymowicz

  • 1Department of Histology and Embryology, Center for Biostructure Research, Medical University of Warsaw, Chałubińskiego 5, 02-004, Warszawa, Poland.

Endocrine Pathology
|January 9, 2013
PubMed

Insights

The mammalian target of rapamycin (mTOR) pathway is notably active in growth hormone-secreting pituitary adenomas (GHomas). However, its activation did not correlate with tumor features or depend on Akt and Erk pathways, suggesting further research is needed.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Tumorigenesis mechanisms in nonfamilial pituitary adenomas remain unclear.
  • Aberrant intracellular signaling pathways, including mammalian target of rapamycin (mTOR), Akt, and Erk, are implicated in various neoplasms.

Purpose of the Study:

  • To investigate mTOR pathway activation in pituitary adenomas.
  • To assess the influence of mTOR pathway activation on tumor morphopathological features.
  • To examine the relationship between Akt, Erk, and mTOR pathway activation.

Main Methods:

  • Western blotting of 53 pituitary adenomas using phospho-specific antibodies.
  • Primary cell cultures treated with selective kinase inhibitors to assess Akt and Erk impact on mTOR.
  • Statistical correlation analysis between kinase activation and morphopathological parameters (size, volume, Ki-67, Knosp's grading, SSTR expression).

Main Results:

  • Growth hormone-secreting adenomas (GHomas) exhibited the highest frequency (71%) and level of mTOR pathway activity compared to other adenomas (33%).
  • No significant correlation was found between mTOR activation and morphopathological features.
  • mTOR phosphorylation was independent of Akt and Erk in primary cultures. Erk activity was high in control samples and inversely correlated with Knosp's grading in nonfunctional adenomas.

Conclusions:

  • The study highlights significant mTOR pathway activity in GHomas.
  • The lack of correlation with tumor features and independence from Akt/Erk suggests a complex role for mTOR in pituitary adenomas.
  • Further investigation is required to elucidate the precise roles of mTOR, Akt, and Erk pathways in pituitary tumorigenesis.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...